文献速递妇科肿瘤

奥拉帕利联合或不联合西地尼布对比铂类化疗治疗复发性铂敏感卵巢癌(NRG-GY004):一项随机、开放标签、III期试验

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
PubMed 文献 · J Clin Oncol · 2022-03-15

NRG-GY004研究在美国和加拿大纳入565例铂敏感高级别浆液性或子宫内膜样卵巢癌患者,随机1:1:1接受铂类化疗、奥拉帕利或奥拉帕利/西地尼布治疗。奥拉帕利/西地尼布对比化疗未改善无进展生存期(HR 0.86,95%CI 0.66-1.10,P=0.077),且患者报告结局评分更差。在胚系BRCA突变患者中,奥拉帕利和奥拉帕利/西地尼布均显示出显著临床活性。

要点

  • 奥拉帕利/西地尼布对比化疗未改善PFS:中位PFS 10.4 vs 10.3个月,HR 0.86(95%CI 0.66-1.10,P=0.077)。
  • 胚系BRCA突变者中,奥拉帕利/西地尼布对比化疗PFS HR 0.55(95%CI 0.32-0.94),奥拉帕利HR 0.63(95%CI 0.37-1.07)。
  • 无胚系BRCA突变者中,奥拉帕利对比化疗PFS HR 1.41(95%CI 1.07-1.86);奥拉帕利/西地尼布HR 0.97(95%CI 0.73-1.30)。

核心结论

  • 奥拉帕利/西地尼布对比铂类化疗未改善PFS,且患者报告结局评分降低。
  • 在胚系BRCA突变患者中,奥拉帕利和奥拉帕利/西地尼布均显示出显著临床活性。

研究设计与样本

  • NRG-GY004是一项在美国和加拿大开展的开放标签、随机、III期试验。
  • 纳入高级别浆液性或子宫内膜样铂敏感卵巢癌患者,随机1:1:1接受铂类化疗、奥拉帕利或奥拉帕利/西地尼布治疗。
  • 2016年2月4日至2017年11月13日期间,共565例合格患者被随机分配。
  • 主要终点为意向治疗人群的无进展生存期(PFS),次要终点包括胚系BRCA突变或野生型亚组的活性和患者报告结局(PROs)。

主要发现

  • 化疗、奥拉帕利和奥拉帕利/西地尼布的中位PFS分别为10.3个月(95%CI 8.7-11.2)、8.2个月(95%CI 6.6-8.7)和10.4个月(95%CI 8.5-12.5)。
  • 奥拉帕利/西地尼布对比化疗的PFS HR为0.86(95%CI 0.66-1.10,P=0.077)。
  • 胚系BRCA突变者中,奥拉帕利/西地尼布对比化疗的PFS HR为0.55(95%CI 0.32-0.94),奥拉帕利对比化疗的HR为0.63(95%CI 0.37-1.07)。
  • 无胚系BRCA突变者中,奥拉帕利/西地尼布对比化疗的PFS HR为0.97(95%CI 0.73-1.30),奥拉帕利对比化疗的HR为1.41(95%CI 1.07-1.86)。
  • 489例可评估PROs的患者中,奥拉帕利/西地尼布组NFOSI-DRS-P子量表评分平均比化疗组差1.1分(97.5%CI -2.0至-0.2,P=0.0063);奥拉帕利与化疗之间未观察到差异。

关键数值与推荐

  • 化疗、奥拉帕利和奥拉帕利/西地尼布的中位PFS分别为10.3个月(95%CI 8.7-11.2)、8.2个月(95%CI 6.6-8.7)和10.4个月(95%CI 8.5-12.5)。
  • 奥拉帕利/西地尼布对比化疗的PFS HR为0.86(95%CI 0.66-1.10,P=0.077)。
  • 胚系BRCA突变者中,奥拉帕利/西地尼布对比化疗的PFS HR为0.55(95%CI 0.32-0.94),奥拉帕利对比化疗的HR为0.63(95%CI 0.37-1.07)。
  • 无胚系BRCA突变者中,奥拉帕利/西地尼布对比化疗的PFS HR为0.97(95%CI 0.73-1.30),奥拉帕利对比化疗的HR为1.41(95%CI 1.07-1.86)。
  • 489例可评估PROs的患者中,奥拉帕利/西地尼布组NFOSI-DRS-P子量表评分平均比化疗组差1.1分(97.5%CI -2.0至-0.2,P=0.0063);奥拉帕利与化疗之间未观察到差异。

临床怎么用

  • 奥拉帕利/西地尼布对比铂类化疗未改善PFS,且患者报告结局评分降低。
  • 在胚系BRCA突变患者中,奥拉帕利和奥拉帕利/西地尼布均显示出显著临床活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, versus platinum-based chemotherapy. PATIENTS AND METHODS: NRG-GY004 is an open-label, randomized, phase III trial conducted in the United States and Canada. Eligible patients had high-grade serous or endometrioid platinum-sensitive ovarian cancer. Patients were randomly assigned 1:1:1 to platinum-based chemotherapy, olaparib, or olaparib/cediranib. The primary end point was progression-free survival (PFS) in the intention-to-treat population. Secondary end points included activity within germline BRCA-mutated or wild-type subgroups and patient-reported outcomes (PROs). RESULTS: Between February 04, 2016, and November 13, 2017, 565 eligible patients were randomly assigned. Median PFS was 10.3 (95% CI, 8.7 to 11.2), 8.2 (95% CI, 6.6 to 8.7), and 10.4 (95% CI, 8.5 to 12.5) months with chemotherapy, olaparib, and olaparib/cediranib, respectively. Olaparib/cediranib did not improve PFS versus chemotherapy (hazard ratio [HR] 0.86; 95% CI, 0.66 to 1.10; P = .077). In women with germline BRCA mutation, the PFS HR versus chemotherapy was 0.55 (95% CI, 0.32 to 0.94) for olaparib/cediranib and 0.63 (95% CI, 0.37 to 1.07) for olaparib. In women without a germline BRCA mutation, the PFS HR versus chemotherapy was 0.97 (95% CI, 0.73 to 1.30) for olaparib/cediranib and 1.41 (95% CI, 1.07 to 1.86) for olaparib. Hematologic adverse events occurred more commonly with chemotherapy; however, nonhematologic adverse events were higher with olaparib/cediranib. In 489 patients evaluable for PROs, patients receiving olaparib/cediranib scored on average 1.1 points worse on the NFOSI-DRS-P subscale (97.5% CI, -2.0 to -0.2, P = .0063) versus chemotherapy; no difference between olaparib and chemotherapy was observed. CONCLUSION: Combination olaparib/cediranib did not improve PFS compared with chemotherapy and resulted in reduced PROs. Notably, in patients with a germline BRCA mutation, both olaparib and olaparib/cediranib had significant clinical activity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Liu JF, Brady MF, Matulonis UA, et al. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2022. PMID: 35290101. doi:10.1200/JCO.21.02011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。